ALX Oncology
ALXO
ALXO
111 hedge funds and large institutions have $293M invested in ALX Oncology in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.91% more ownership
Funds ownership: 91.3% → 93.2% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
43% less capital invested
Capital invested by funds: $510M → $293M (-$218M)
Holders
111
Holding in Top 10
2
Calls
$3.33M
Puts
$1.9M
Top Buyers
| 1 | +$19.4M | |
| 2 | +$15.6M | |
| 3 | +$12.2M | |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$11.2M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$6.32M |
Top Sellers
| 1 | -$35M | |
| 2 | -$14.3M | |
| 3 | -$10.1M | |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$3.57M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.73M |